| Primary |
| Abdominal Infection |
11.1% |
| Pneumonia |
10.4% |
| Sepsis |
9.7% |
| Peritonitis |
7.9% |
| Acinetobacter Infection |
6.9% |
| Cellulitis |
5.3% |
| Infection |
5.3% |
| Staphylococcal Infection |
5.2% |
| Hypertension |
5.1% |
| Prophylaxis |
4.5% |
| Bronchopneumonia |
3.8% |
| Osteomyelitis |
3.5% |
| Pain |
2.9% |
| Product Used For Unknown Indication |
2.9% |
| Diabetic Foot Infection |
2.7% |
| Septic Shock |
2.7% |
| Drug Use For Unknown Indication |
2.6% |
| Skin Infection |
2.6% |
| Multiple-drug Resistance |
2.5% |
| Mycobacterium Abscessus Infection |
2.5% |
|
| Pancreatitis |
14.3% |
| Death |
10.8% |
| Thrombocytopenia |
8.9% |
| Nausea |
7.9% |
| Vomiting |
6.9% |
| Sepsis |
5.9% |
| Drug Ineffective |
5.7% |
| Pathogen Resistance |
4.9% |
| Septic Shock |
4.4% |
| Hepatic Failure |
3.9% |
| Hypoglycaemia |
3.2% |
| Pancreatitis Acute |
3.2% |
| Multi-organ Failure |
3.0% |
| Rash |
2.7% |
| Staphylococcal Infection |
2.7% |
| Hepatotoxicity |
2.5% |
| Infection |
2.5% |
| Jaundice |
2.2% |
| Pneumonia Bacterial |
2.2% |
| White Blood Cell Count Increased |
2.2% |
|
| Secondary |
| Sepsis |
12.8% |
| Pneumonia |
9.5% |
| Acinetobacter Infection |
8.3% |
| Peritonitis |
7.5% |
| Enterococcal Infection |
7.2% |
| Abdominal Infection |
6.8% |
| Peritoneal Abscess |
5.0% |
| Bacteraemia |
4.7% |
| Candidiasis |
4.3% |
| Staphylococcal Infection |
4.3% |
| Multiple-drug Resistance |
3.8% |
| Endocarditis |
3.5% |
| Cellulitis |
3.3% |
| Osteitis |
3.2% |
| Prophylaxis Against Transplant Rejection |
3.0% |
| Escherichia Infection |
2.7% |
| Generalised Oedema |
2.7% |
| Abdominal Abscess |
2.5% |
| Lung Infection |
2.5% |
| Osteomyelitis |
2.5% |
|
| Pathogen Resistance |
11.5% |
| Drug Ineffective |
9.0% |
| Thrombocytopenia |
9.0% |
| Sepsis |
7.5% |
| Death |
7.0% |
| Renal Failure Acute |
7.0% |
| Multi-organ Failure |
6.0% |
| Pancreatitis |
5.0% |
| Pneumonia Bacterial |
5.0% |
| Septic Shock |
5.0% |
| Pseudomonas Infection |
4.0% |
| Vomiting |
3.5% |
| Fistula |
3.0% |
| Gastrointestinal Haemorrhage |
3.0% |
| Respiratory Failure |
3.0% |
| Staphylococcal Infection |
3.0% |
| Pancreatitis Acute |
2.5% |
| Asthenia |
2.0% |
| Blood Urea Increased |
2.0% |
| Carotid Aneurysm Rupture |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.4% |
| Drug Use For Unknown Indication |
32.8% |
| Crohn's Disease |
3.0% |
| Sleep Disorder |
2.7% |
| Graft Versus Host Disease |
2.4% |
| Infection |
2.4% |
| Renal Failure |
2.3% |
| Haemolytic Uraemic Syndrome |
2.2% |
| Stenotrophomonas Infection |
2.0% |
| Hypertension |
1.8% |
| Diabetes Mellitus |
1.7% |
| Diarrhoea |
1.7% |
| Depression |
1.5% |
| Premedication |
1.3% |
| Thrombosis Prophylaxis |
1.2% |
| Cardiac Fibrillation |
1.1% |
| Coronary Artery Disease |
1.1% |
| Cytomegalovirus Infection |
1.1% |
| Dialysis |
1.1% |
| Gastritis Prophylaxis |
1.1% |
|
| Vomiting |
21.2% |
| Sepsis |
15.3% |
| Pneumonia |
9.4% |
| Stenotrophomonas Infection |
9.4% |
| Acute Respiratory Distress Syndrome |
4.7% |
| Death |
4.7% |
| Fungal Endocarditis |
4.7% |
| Aspartate Aminotransferase Increased |
3.5% |
| Pancytopenia |
3.5% |
| Bradyarrhythmia |
2.4% |
| Bronchopulmonary Aspergillosis |
2.4% |
| Gastrointestinal Haemorrhage |
2.4% |
| Grand Mal Convulsion |
2.4% |
| Intra-uterine Death |
2.4% |
| Leukopenia |
2.4% |
| Pain |
2.4% |
| Septic Shock |
2.4% |
| Weight Decreased |
2.4% |
| Abdominal Pain |
1.2% |
| Anaemia |
1.2% |
|
| Interacting |
| Pulmonary Embolism |
50.0% |
| Abdominal Infection |
25.0% |
| Diverticular Perforation |
25.0% |
|
| Pulmonary Embolism |
100.0% |
|
